Identification of Drug Resistance Determinants in a Clinical Isolate of *Pseudomonas aeruginosa* by High-Density Transposon Mutagenesis

Michael S. Sonnabend,a,b Kristina Klein,a Sina Beier,c Angel Angelov,a,b Robert Kluj,d Christoph Mayer,d Caspar Groß,a Kathrin Hofmeister,a Antonia Beuttner,a Matthias Willmann,a,b Silke Peter,a,b Philipp Oberhettinger,a Annika Schmidt,a Ingo B. Autenrieth,a,b Monika Schütz,a Erwin Bohna

---

**ABSTRACT** With the aim to identify potential new targets to restore antimicrobial susceptibility of multidrug-resistant (MDR) *Pseudomonas aeruginosa* isolates, we generated a high-density transposon (Tn) insertion mutant library in an MDR *P. aeruginosa* bloodstream isolate (isolate ID40). The depletion of Tn insertion mutants upon exposure to cefepime or meropenem was measured in order to determine the common resistome for these clinically important antipseudomonal β-lactam antibiotics. The approach was validated by clean deletions of genes involved in peptidoglycan synthesis/recycling, such as the genes for the lytic transglycosylase MltG, the murein (Mur) endopeptidase MepM1, the MurNAC/GlcNAc kinase AmgK, and the uncharacterized protein YgfB, all of which were identified in our screen as playing a decisive role in survival after treatment with cefepime or meropenem. We found that the antibiotic resistance of *P. aeruginosa* can be overcome by targeting usually nonessential genes that turn essential in the presence of therapeutic concentrations of antibiotics. For all validated genes, we demonstrated that their deletion leads to the reduction of *ampC* expression, resulting in a significant decrease in β-lactamase activity, and consequently, these mutants partly or completely lost resistance against cephalosporins, carbapenems, and acylaminopenicillins. In summary, the determined resistome may comprise promising targets for the development of drugs that may be used to restore sensitivity to existing antibiotics, specifically in MDR strains of *P. aeruginosa*.

**KEYWORDS** *Pseudomonas aeruginosa*, multidrug resistance, antibiotics, TraDIS, clinical isolate, peptidoglycan recycling, AmpC β-lactamase, peptidoglycan

---

*Pseudomonas aeruginosa* is one of the most important pathogens involved in nosocomial infections, such as pneumonia, urinary tract infections, wound infections, and potentially life-threatening bloodstream infections. In particular, intensive care and immunocompromised patients are at risk for the development of severe infections. Multidrug-resistant (MDR) strains are emerging, which makes the treatment of *P. aeruginosa* infections even more difficult. For this reason, WHO ranked carbapenem-
resistant *P. aeruginosa* in the top class of its list of priority pathogens for which new antibiotics are urgently needed (1). For an increasing number of cases, colistin is the last treatment option, despite its neuro- and nephrotoxic side effects.

*P. aeruginosa* employs various intrinsic and acquired antibiotic resistance mechanisms. The high intrinsic resistance is mainly caused by the very low permeability of the outer membrane (2) and the inducible expression of efflux pumps and enzymes mediating resistance, like AmpC (3). *ampC* is expressed at a low level in wild-type (WT) strains, but its expression can be strongly increased in strains in which *ampC* is derepressed. Derepression of *ampC* is often caused by mutations in the transcriptional regulator AmpR in AmpD (4, 5) or in the *dacB* gene, encoding muropeptide amidase and penicillin-binding protein 4 (PBP4), respectively (6), leading to an increased pool of 1,6-anhydromuropeptides originating from the peptidoglycan (PG) recycling pathway (7). Moreover, *ampC* expression can be induced by β-lactam antibiotics and β-lactamase inhibitors, leading to resistance against most β-lactam antibiotics (8).

One strategy that may be used to reconsider the use of antibiotics that have become ineffective because of the development of resistance is inactivation of the primary resistance mechanism. Thus, the combination of β-lactam antibiotics and β-lactamase inhibitors, such as tazobactam, which block the activity of β-lactamases, makes it possible to reconsider the use of antibiotics such as piperacillin. However, such combinations often fail again to kill microbial pathogens because of β-lactamases which are resistant to the β-lactamase inhibitors (9–11). One upcoming strategy is to use a different class of antibiotic adjuvants. Such adjuvants would not inactivate a primary resistance mechanism but, rather, would act on a secondary resistance gene. Several examples for such a strategy have been described (12–16). In this study, we wanted to find out which proteins can serve as targets to resensitize MDR *P. aeruginosa* strains to treatment with β-lactam antibiotics.

To answer this question, we performed transposon (Tn)-directed insertion sequencing (TraDIS) using the clinical bloodstream isolate ID40, which is resistant to many β-lactam antibiotics, to assess the resistome of *P. aeruginosa* by an approach similar to that described by Jana et al. (17). TraDIS has been shown to be a valuable tool under particular conditions and in various approaches to find genes responsible for growth (18–21). We constructed a Tn mutant library in the MDR ID40 strain and subjected it to cefepime (FEP) or meropenem (MEM) treatment. TraDIS revealed nonessential candidate genes, including well-known genes as well as so far unknown genes, whose inactivation breaks the resistance against these antibiotics. Some candidates were verified by testing the respective deletion mutants for their antibiotic sensitivity, β-lactamase activity, and *ampC* expression. The presence of these genes seems to be crucial to achieve or maintain antibiotic resistance. These genes may comprise the most promising nonessential target genes for the development of novel antibiotic adjuvants to reconsider the use of β-lactam antibiotics for the treatment of infections caused by resistant strains of *P. aeruginosa*.

**RESULTS**

**ID40 sequence and resistance profile.** To determine the resistome of an MDR *P. aeruginosa* strain against β-lactam antibiotics, we used the bloodstream isolate ID40 (22). ID40 belongs to sequence type 252 (ST-252; determined by use of multilocus sequence typing [MLST 2.0, Center for Genomic Epidemiology, DTU, Denmark] [23]) and is resistant to piperacillin (PIP), piperacillin-tazobactam (TZP), cefepime (FEP), ceftazidime (CAZ), aztreonam (ATM), levofloxacin (LEV), ciprofloxacin (CIP), and imipenem (IMP). Moreover, ID40 is intermediate for meropenem (MEM) and sensitive to amikacin (AMI), gentamicin (GEN), tobramycin (TOB), and colistin (COL) (see Table S1 in the supplemental material). The whole genome and the plasmid sequence were annotated and submitted to the European Nucleotide Archive (ENA; [https://www.ebi.ac.uk/ena; accession number PRJEB32702](https://www.ebi.ac.uk/ena; accession number PRJEB32702)). The ID40 chromosome is 6.86 Mbp in size, encodes 6,409 open reading frames, and carries a plasmid of 57,446 bp comprising 59 putative genes. Resistance genes were
searched for using the ResFinder tool (24), revealing the following resistance genes: aph(3′)-IIb (neo) for aminoglycoside resistance, blaoxa-486 (bla) and oxaPAO1 (ampC, PDC-3) for β-lactam resistance, crpP for fluoroquinolone resistance, and fosA (fosA_1) for fosfomycin resistance. Additionally, we found a point mutation in the dacB gene (PBP4; G to A at nucleotide 1310, G437D), which is known to be responsible for resistance against β-lactam antibiotics, as shown by an increased MIC for CAZ from 1 μg/ml to 32 μg/ml in P. aeruginosa PAO1 (6). Therefore, the mutation in dacB most likely rationalizes the different resistance level of ID40 in comparison to that of strain PA14, which contains the same resistance genes but is sensitive to all β-lactam antibiotics. Other resistance mechanisms, like the reduced expression of oprD and overexpression of efflux pumps, were not specifically addressed, but the possibility of their contribution to resistance cannot be finally excluded. Analysis of the OprD sequence and comparison to the literature did not provide any clear evidence that OprD of ID40 is dysfunctional (25–28).

**Construction of a high-density mutant library and TraDIS sequencing.** Growth of the Tn library in lysogeny broth (LB) revealed approximately 100,000 unique Tn insertions distributed across the genome, with an average of 18 Tn insertion sites per 1 kbp of coding sequence. The homogeneous distribution of the Tn insertions and the homogeneous coverage of the whole genome are shown in Fig. S1.

Analysis of the unchallenged Tn library showed that of 6,468 genes, 697 genes were determined to be essential for viability (10.8%) (Data Set S1) and 9 were determined to be ambiguous (0.14%) (Data Set S2). Among these, many genes, for example, dnaA, gyrB, or lolA, were previously described to be essential (29, 30).

**Identification of genes important for resistance against meropenem and cefepime.** The contribution of nonessential genes to antimicrobial resistance was measured by quantifying the depletion of Tn insertion mutants upon exposure to FEP and MEM at the respective breakpoint concentration, defining a P. aeruginosa strain to be sensitive according to EUCAST breakpoints (for FEP, 8 μg/ml; for MEM, 2 μg/ml). For analysis of the TraDIS results, we chose only genes in which the read number in the LB control was >10 in all three independent experiments and which additionally showed a significant change in read counts upon treatment with an adjusted P value of <0.05 (Data Set S3). Genes that showed a significant change in read counts in comparison to those for the untreated sample are visualized in Fig. 1. In total, 140 genes fulfilled these criteria upon MEM treatment and 102 genes fulfilled these criteria upon FEP treatment. Nonessential genes in which the read counts for Tn insertion were reduced at least 5-fold with a high level of significance (adjusted P value < 0.05) are listed in Table 1. In total, 24 such genes were identified. Thirteen of those genes fulfilled these criteria for both MEM and FEP, 5 fulfilled these criteria only for MEM, and 6 fulfilled these criteria only for FEP. Most genes were found to be involved in PG synthesis and recycling. The most interesting genes identified in this screening were those which showed a significant reduction in read counts after both MEM and FEP treatment. All TraDIS sequence data were uploaded to ENA (accession number PRJEB32702).

We found several genes dedicated to PG recycling metabolism, such as ampG and nagZ, known to be important for resistance against β-lactam antibiotics (31–36). In addition, the efflux pump genes mexA and mexB (Data Set S3) as well as the porin OprF were also identified in our screen and have been described to be involved in antibiotic resistance (37) (Table 1). This finding points out that our approach can identify nonessential genes involved in antibiotic resistance.

A pathway that connects cell wall recycling to PG de novo biosynthesis is responsible for the intrinsic resistance of P. aeruginosa to fosfomycin, inhibiting the synthesis of PG by blocking the formation of N-acetylmuramic acid (MurNAc) (38–41). This cell wall salvage pathway comprises anhydro-MurNAc kinase (AnmK), an anomeric cell wall amino sugar kinase (AmgK), MurNAc-6-phosphatase (MupP), and an uridylyltransferase (MurU), together converting 1,6-anhydro-N-acetylmuramic acid (AnhMurNAc) to UDP-
MurNAc, thereby bypassing the fosfomycin-sensitive de novo synthesis of UDP-MurNAc. We identified the genes for all four of these enzymes (Table 1) and conclude that the anabolic recycling pathway may play a critical role in maintaining resistance against β-lactam antibiotics, at least in strains with high levels of β-lactamase activity.

Moreover, genes encoding the lytic transglycosylases (LTs) Slt and MltG were found to be associated with resistance upon treatment with MEM and FEP (Table 1). The loss of Slt was shown to reduce resistance against β-lactam antibiotics in PAO1 (42). MltG was described as one of several LTs to be inhibited by bulgecin, a sulfonated glycopeptide originally isolated from *P. acidophila* and *P. mesoacidophila*, resulting in slightly reduced MICs of CAZ and MEM (16).

MepM1 (YeBA, PA0667) belongs to a group of murein endopeptidases (EPs) which putatively modulate PG cross-linking (43). A study revealed that the protease CtpA (PA5134) inactivates various EPs, namely, those encoded by PA0667 (TUEID40_04290 or mepM1), PA4404 (TUEID40_02316), PA1198 (TUEID40_01415), and PA1199 (TUEID40_01414), and thereby controls the level of PG cross-linking (43). TUEID40_01414 also showed reduced read counts upon treatment with MEM and/or FEP, but to a much lesser extent than MepM1 did (Data Set S3). In addition, the EP MepM2, which is not regulated by CtpA, at least in the *P. aeruginosa* PAK strain (43), also seems to be involved in maintaining antibiotic resistance (Table 1).
| Category | Identifier | Gene | Name/function | MEM vs LB Ratio | MEM vs LB P value | FEP vs LB Ratio | FEP vs LB P value | Orthologue(s) |
|----------|------------|------|---------------|-----------------|-------------------|----------------|-------------------|---------------|
| **Resistance** | TUED40_04486 | ampC | ß-Lactamase | 0.07 | 0.00052 | 0.05 | 3.87E-5 | PA14_10770, PA4110 |
| | TUED40_05675 | slh | Soluble lytic transglycosylase | 0.02 | 5.08E-13 | 0.03 | 3.61E-10 | PA14_25000, PA3020 |
| | TUED40_05736 | mltG | Endolysin murein transglycosylase | 0.02 | 1.32E-33 | 0.03 | 1.77E-41 | PA14_25730, PA2963 |
| | TUED40_04290 | mepM1 | Murin co-endopeptidase | 0.05 | 1.01E-07 | 0.07 | 2.29E-06 | PA14_08540, PA6667 |
| | TUED40_02325 | ftsW | Synthesis of septal peptidoglycan during cell division | 0.11 | 2.76E-05 | 0.20 | 0.0019 | PA14_57360, PA4113 |
| | TUED40_02305 | ampG | Permease | 0.02 | 7.08E-30 | 0.03 | 3.61E-29 | PA14_57100, PA4939 |
| | TUED40_05690 | nagZ | ß-N-Acetyl-ß-glucosaminidase | 0.07 | 1.56E-05 | 0.04 | 6.23E-06 | PA14_25193, PA3005 |
| | TUED40_04289 | anmK | Anhydro-N-acetylmuramic acid kinase | 0.12 | 4.93E-10 | 0.20 | 1.62E-06 | PA14_08520, PA6666 |
| | TUED40_04233 | mepM2 | Murein DD-endopeptidase MepM, unknown function | 0.08 | 3.05E-06 | 0.17 | 0.0085 | PA14_07780, PA0596 |
| | TUED40_04234 | hddC | Similar to N-acetylmuramyl alpha-1-phosphate uridylyltransferase MurU of Pseudomonas putida | 0.07 | 5.10E-05 | 0.15 | 0.0001 | PA14_07790, PA0597 |
| | TUED40_00881 | mepM2 | Murin co-endopeptidase MepM, unknown function | 0.14 | 3.60E-12 | 0.37 | 0.002 | PA14_15100, PA3787 |
| | TUED40_03621 | tetP | Type IV pili secretin-associated protein; anchors the outer membrane type IV pili secretin complex to the peptidoglycan | 0.02 | 1.00E-28 | 0.31 | 3.61E-10 | PA14_00210, PA0020 |
| | TUED40_01638 | bepA | ß-Barrel assembly enhancing protease | 0.12 | 2.17E-07 | 0.24 | 1.20E-06 | PA14_51320, PA1005 |
| | TUED40_03216 | ygbB | YgbB-like proteins, unknown | 0.14 | 6.06E-05 | 0.21 | 0.001 | PA14_08640, PA5196 |
| | TUED40_05674 | tucC | Glycosyltransferase family 1 | 0.02 | 8.35E-09 | 0.02 | 7.79E-10 | PA14_69010, PA5225 |

**Data are for genes for which insertion sequence abundance was significantly reduced (>5-fold; adjusted P value, <0.05) upon exposure to 2 µg/ml MEM or 8 µg/ml FEP. Differences in insertion sequence abundance are expressed as the mean of the ratio of the normalized sequence read numbers of antibiotic-treated culture in relation to the normalized sequence read numbers of the LB control culture of the Tn library. In total, three independent experiments were performed.**
Furthermore, we identified two so far unknown or uncharacterized candidate genes putatively involved in antibiotic resistance against both MEM and FEP: TUEID40_05543 (\textit{tuaC}) belongs to the glycosyltransferase 1 family, and TUEID40_03245 encodes a YgfB-like protein with a so far unknown function which is referred to here as YgfB.

**Confirmation of selected genes involved in antimicrobial resistance.** To validate our TraDIS results, deletion mutants for \textit{mltG}, \textit{mepM1}, \textit{amgK}, \textit{ygfB}, \textit{tuaC}, and \textit{ctpA}, as well as a \textit{ctpA} \textit{mepM1} double mutant, were tested for their sensitivity against \textit{β}-lactam antibiotics. Both microdilution assays indicated that the deletion of \textit{mltG}, \textit{mepM1}, \textit{ygfB}, and \textit{amgK} reduced the MIC values for all tested \textit{β}-lactam antibiotics (Table 2) except for IMP (\textit{ΔmepM1} mutant) and MEM (\textit{ΔmepM1} and \textit{ΔamgK} mutants), while deletion of \textit{tuaC} resulted in only a slight reduction in the MIC for TZP. The MIC values were reduced below the breakpoint for FEP and ATM in the \textit{ΔmltG}, \textit{ΔmepM1}, \textit{ΔygfB}, and \textit{ΔamgK} mutants and for CAZ in the \textit{ΔmltG} and \textit{ΔamgK} mutants. Additionally, the \textit{ΔmltG} mutant showed MICs below the breakpoint for PIP, TZP, and IMP. These data confirm the validity of the TraDIS screen and demonstrate the contribution of these genes to resistance against \textit{β}-lactam antibiotics in the ID40 strain.

Deletion of \textit{ctpA} increased the MIC values for MEM, FEP, PIP, and ATM. Thus, we hypothesize that the increased activity of MepM1 and other CtpA substrates leads to increased resistance. The MIC values of PIP and ATM for the \textit{ΔctpA} \textit{ΔmepM1} double mutant were lower than those for the \textit{ΔctpA} mutant but higher than those for the \textit{ΔmepM1} deletion mutant, indicating that the other substrates of CtpA might also contribute to resistance against \textit{β}-lactam antibiotics and compensate for the loss of MepM1 without the inactivation of CtpA. According to the TraDIS data, the most promising CtpA-regulated substrates which may, in combination with MepM1, contribute to \textit{β}-lactam resistance are TUEID40_02316 and TUEID40_01415 (Data Set S3). Furthermore, it could be confirmed that the deletion of \textit{amgK} resulted in reduced resistance against fosfomycin (Table 2 and Table S1), as previously described (39).

For complementation, conditional mutants (the \textit{ΔmltG::mltG}, \textit{ΔmepM1::mepM1}, \textit{ΔctpA::ctpA}, and \textit{ΔygfB::ygfB} mutants) in which the complemented genes were under the control of a rhamnose-inducible promoter were generated. Complementation could be achieved in the presence of 0.1% rhamnose (Table S1).

\textit{MltG}, \textit{MepM1}, \textit{AmgK}, and \textit{YgfB} contribute to \textit{β}-lactam resistance in ID40 by promoting \textit{ampC} expression. To assess in more detail the reason why the mutants show restored susceptibility to \textit{β}-lactam antibiotics, we measured the \textit{β}-lactamase activity of ID40, the different deletion mutants, as well as the laboratory strain PA14, which is sensitive to all tested antibiotics (Table 2). As determined by a nitrocefin-based assay, \textit{β}-lactamase activity was strongly reduced in the \textit{ΔmltG}, \textit{ΔmepM1}, \textit{ΔygfB}, and \textit{ΔamgK} mutants, with the most profound reduction being seen in the \textit{ΔmltG} mutant, showing \textit{β}-lactamase activity almost as low as that of the PA14 strain (Fig. 2A) and

**Table 2 Susceptibility of ID40 WT and deletion mutants to \textit{β}-lactam antibiotics.**

| Antibiotic | Breakpoint | \textit{ΔmltG} mutant | \textit{ΔmepM1} mutant | \textit{ΔctpA} mutant | \textit{ΔmepM1} mutant | \textit{ΔygfB} mutant | \textit{ΔamgK} mutant | \textit{ΔtuaC} mutant | PA14 |
|------------|------------|----------------------|-----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|-------|
| MEM        | Susceptible | 2                    | 4                     | 4                    | 16                   | 16                   | 8                    | 8                    | 8     |
|            | Resistant   | 8                    | 8                     | 16                   | 16                   | 8                    | 8                    | 8                    | 8     |
| IMP        | Susceptible | 4                    | 4                     | 32                   | 32                   | 32                   | 8                    | 8                    | 8     |
|            | Resistant   | 4                    | 4                     | 32                   | 32                   | 32                   | 8                    | 8                    | 8     |
| FEP        | Susceptible | 8                    | 8                     | 4                    | 4                    | 32                   | 32                   | 32                   | 8     |
|            | Resistant   | 16                   | 16                    | 32                   | 32                   | 32                   | 8                    | 8                    | 8     |
| CAZ        | Susceptible | 8                    | 8                     | 32                   | 2                    | 16                   | >32                  | 32                   | 8     |
|            | Resistant   | 16                   | 16                    | 128                  | 4                    | 64                   | >128                 | 128                  | <4    |
| PIP        | Susceptible | 16                   | 16                    | 128                  | 4                    | 64                   | >128                 | 128                  | <4    |
|            | Resistant   | 16                   | 16                    | 128                  | 4                    | 64                   | >128                 | 128                  | <4    |
| TZP        | Susceptible | 16                   | 16                    | 128                  | 4                    | 64                   | >128                 | 128                  | <4    |
|            | Resistant   | 16                   | 16                    | 128                  | 4                    | 64                   | >128                 | 128                  | <4    |
| ATM        | Susceptible | 16                   | 16                    | 32                   | 2                    | 16                   | >32                  | 32                   | 8     |
|            | Resistant   | 16                   | 16                    | 32                   | 2                    | 16                   | >32                  | 32                   | 8     |
| FOS        | Susceptible | 96                   | 96                    | 96                   | 96                   | 64                   | 728                  | 48                   | 48    |
|            | Resistant   | 96                   | 96                    | 96                   | 96                   | 64                   | 728                  | 48                   | 48    |

\textsuperscript{a}MICs of ID40 WT and deletion mutant strains were determined by broth microdilution or by Etest for fosfomycin. Susceptible was an MIC less than or equal to the breakpoint, and resistance was an MIC greater than the breakpoint. MIC values for the deletion mutants lower than the MIC for the ID40 WT are in bold, and MICs below the MIC breakpoint are in bold and underlined. MIC values higher than the MIC for the ID40 WT are in italics. MEM, meropenem; IMP, imipenem; FEP, cefepime; CAZ, ceftazidime; PIP, piperacillin; TZP, piperacillin-tazobactam; ATM, aztreonam; FOS, fosfomycin.
being sensitive to all β-lactam antibiotics tested (Table S1). The β-lactamase activity corresponded directly to the MIC values for the different mutants. Similarly, higher β-lactamase activity was found in the hyperresistant ΔctpA mutant. Therefore, the changes in MICs for the mutants from those for the ID40 wild type are presumably caused by altered β-lactamase activity. No significant change in β-lactamase activity was found between the ΔctpA ΔmepM1 mutant and the ΔctpA mutant, indicating that the uncontrolled levels of other CtpA substrates can compensate for the lack of MepM1.

The ID40 genome encodes two β-lactamases (ampC and bla_{OXA-486} [bla or poxB]). For PoxB, it has been shown that it does not contribute to β-lactam resistance (44). We quantified the expression level of ampC to investigate whether the lower β-lactamase activity is due to reduced ampC expression. Semiquantitative reverse transcription-PCR revealed that the deletion of mltG, mepM1, amgK, or ygfB significantly decreased ampC mRNA expression (Fig. 2B). Deletion of ctpA, presumably resulting in a higher level of MepM1 and its other substrates, caused an increase in ampC expression. The expression level of ampC in the different mutants was in agreement with the levels of β-lactamase.

**FIG 2** β-Lactamase activity and ampC expression in selected deletion mutants. WT and deletion mutant strains were subcultured, and β-lactamase activity was measured by a nitrocefin turnover assay (A) or expression of the ampC β-lactamase gene was determined by qRT-PCR (B) in at least 3 independent experiments. Graphs depict the means and SDs. Student’s t test was performed for determination of the difference in the results for each mutant strain in comparison to those for the WT. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
activity and the MICs of β-lactam antibiotics that we measured. These results indicate that the different levels of resistance of the ID40 mutants are due to different levels of ampC expression.

**DISCUSSION**

Here, we report the first application, to our knowledge, of TraDIS to an MDR *Pseudomonas aeruginosa* strain and the evaluation of its nonessential resistome upon exposure to two clinically relevant β-lactam antibiotics. The identified genes might represent targets that could be exploited to resensitize resistant strains so that infections caused by these strains may be treated with β-lactam antibiotics.

Many of the genes important for high-level β-lactam resistance found in the TraDIS approach are part of the PG recycling pathway of *P. aeruginosa* (45), showing its critical role for β-lactam resistance in ID40 (46). A simplified scheme of the PG recycling and synthesis pathway of *P. aeruginosa* and the genes identified by the TraDIS approach as well as genes described to modulate resistance against β-lactam antibiotics is summarized in Fig. 3.

**Players in the periplasm.** The precursors of the PG catabolites contributing to the transcriptional regulation of ampC are generated in the periplasm. LTs (such as MltG and Slt), together with low-molecular-mass penicillin-binding proteins, EPs (such as MepM1), and amidases (such as AmpDh2 and 3), cleave the PG layer to facilitate the insertion of new glycan strands and simultaneously release PG degradation products from the matrix into the cytoplasm (45).

Upon treatment with antibiotics, the strongest impact on LTs in the screening was found for *mltG* and *slt*. In addition, and in agreement with the findings of previous studies (16, 42, 47), we also found that the LTs *mltF* and *mltD* maintain resistance, but to a lesser extent than *slt* and *mltG* (see Data Set S3 in the supplemental material). On the other hand, *sltB* and *sltH* seem to counteract resistance (Data Set S3). The recently described MltG may act as a terminase and determine PG chain length (48). Deletion of *mltG* in ID40 significantly reduced ampC expression and, consequently, β-lactamase activity and broke resistance against IMP, FEP, CAZ, PIP, TZP, and ATM. These findings confirm the validity of our study and underline the importance of MltG for the induction of ampC expression in ID40. As previously demonstrated, MltG, Slt, and MltD are targets of the LT inhibitor bulgecin, reducing the MIC against β-lactam antibiotics (16). According to our data, LTs represent one of the most promising targets for resensitization to treatment with β-lactam antibiotics.

EPs may also contribute to the induction of ampC expression. As demonstrated previously, the protease CtpA inactivates and thereby determines the levels of four EPs that control PG cross-linking (43). Of this group, *mepM1* showed the highest reduction of Tn insertion read counts when treatment with antibiotics and the control were compared, while Tn insertions in PA1198 (TUEID40_01415) had a minor impact on growth in the presence of MEM. In addition, *mepM2* (TUEID40_04881), a further EP which is not regulated by CtpA in strain PAK (43), also seems to contribute to resistance against β-lactam antibiotics. While deletion of *mepM1* leads to reduced MIC values of β-lactam antibiotics, deletion of *ctpA* leads to hyperresistance, probably by deregulating the levels of its substrates. The role of deleted or nonfunctional CtpA in mediating hyperresistance is further supported by the findings of a study by Sanz-García et al., who showed that upon ceftazidime-avibactam treatment, mutations in the ctpA gene emerge and that these lead to resistance (49). Additional deletion of *mepM1* in the ctpA mutant reduces MIC values compared to those for the ΔctpA mutant for PIP and ATM but results in still higher MIC values compared to those for the *mepM1* deletion mutant, indicating that other CtpA-dependent EPs also contribute to the upregulation of ampC expression. These data suggest that the high level of activity of MepM1 promotes increased ampC expression. Thus, inhibition of several of these EPs could be a possible way to break antibiotic resistance.

**Players in the cytoplasm.** After PG catabolites have been formed in the periplasm, they are transported into the cytoplasm by the permease AmpG and partly by AmpP.
In the following process, the 1,6-anh-MurNAc-peptides are degraded by LdcA, NagZ, and AmpD. The amidase AmpD cleaves the peptide chain attached to 1,6-anhMurNAc so that the generated 1,6-anhMurNAc can subsequently be recycled to UDP-MurNAc by the so-called cell wall salvage pathway via AnmK, MupP, AmgK, and MurU, which bypasses the de novo biosynthesis of UDP-MurNAc (38, 39). Finally, UDP-MurNAc is modified by the Mur enzymes to form UDP-MurNAc-pentapeptide (45). Both 1,6-anhMurNAc-peptides and UDP-MurNAc-pentapeptide can bind to the ampC regulator AmpR. Thereby, 1,6-anhMurNAc-peptides induce ampC expression, while UDP-MurNAc-pentapeptide bound to AmpR represses ampC expression.
As observed in our TraDIS data and as also shown previously, the loss of AmpG or NagZ results in decreased amounts of 1,6-anhMurNAc-peptides and hence results in increased susceptibility to β-lactam antibiotics (32, 47). On the other hand, the loss of AmpD leads to the accumulation of 1,6-anhMurNAc-peptides and, therefore, increased ampC expression (51) and is a frequent cause of high levels of ampC expression in clinical isolates of P. aeruginosa (52, 53).

**Players of the cell wall salvage pathway.** The individual deletion of each of the 4 genes (amnK, mupP, amgK, and murU) of the cell wall salvage pathway in PAO1 has been shown to lead to increased β-lactamase activity and a subtle increase in the levels of resistance against cefotaxime and CAZ (41). Although this effect cannot be explained so far, it was proposed that it might be due to the reduction of the steady-state level of the ampC repressor UDP-MurNAc-pentapeptide. Consequently, 1,6-anhMurNAc-peptides would be more likely to bind to AmpR and thereby induce ampC expression (41). In contrast, another study showed that the deletion of amgK also in P. aeruginosa PAO1 had no impact on CAZ or IMP resistance (39), which could be confirmed in our study for all β-lactam antibiotics tested (Table S1). Interestingly, in our study we observed that Tn insertions in all genes of the MurU pathway reduced the level of β-lactam resistance. Validation of the screening results using an amgK deletion mutant confirmed these results. This finding is indeed counterintuitive, and more detailed explorations are necessary to clarify this issue. Presumably, the anabolic recycling pathway somehow counteracts the derepression of ampC in the dacB background of ID40.

**Uncharacterized players.** Additionally, we identified several uncharacterized genes in the TraDIS screening whose results are presented here. Since deletion of the gene tuaC showed only a slight reduction in the MICs against some β-lactam antibiotics, we focused on TUEID40_03245, which we termed ygfB due to its similarity to the homologous gene in *Escherichia coli*. Deletion of ygfB resulted in decreased ampC expression and β-lactamase activity and broke resistance against FEP and ATM in ID40. To our best knowledge, this gene has so far not been described in the context of antibiotic resistance. ygfB is located in an operon together with the pepP, ubiH, a PA14_68970 orthologue, and ubil. ubil and ubih are essential genes important for ubiquinone biosynthesis. Similar operon structures are found also in *E. coli*, *Acinetobacter baumannii*, and *Legionella pneumophila*. *P. aeruginosa* YgfB shares 33% identical amino acids with *E. coli* and *A. baumannii* YgfB and 32% with *L. pneumophila* YgfB. Interestingly, the aminopeptidase gene pepP, which exists in a region adjacent to ygfB, was also identified in the TraDIS screening, but Tn insertion read counts indicate that a lack of pepP might contribute to hyperresistance.

Moreover, experiments with PAO1 Tn mutants suggested that *P. aeruginosa* YgfB may contribute to virulence in a *Caenorhabditis elegans* infection model (54). In addition, a TraDIS experiment suggested that the ygfB orthologue PA14_69010 may play a role in effective colonization in the cecum of mice (55). Thus, the possible role in virulence as well as the ability to modulate antibiotic resistance could mean that this gene is of interest as a target for the development of antibiotic adjuvants which might additionally reduce virulence. In further studies, we will address the function of YgfB and its specific role in mediating antibiotic resistance.

In conclusion, using TraDIS we identified a set of nonessential genes which are crucial for the induction of ampC expression and β-lactam resistance. As shown in a recent study, overexpression of ampC is the most frequent cause for the development of resistance in strains capable of expressing ampC, as shown by the acquisition of mutations in dacB, ampD, and mpl after exposure of the *P. aeruginosa* PAO1 WT to increasing concentrations of ceftazidime (56). However, there are additional mechanisms for the development of resistance against β-lactam antibiotics which gain more importance when ampC expression is hindered. Mutations in ftsI leading to a modification of PBP3 (the target of β-lactam antibiotics), mutations, or overexpression of the efflux pump MexAB-OprM, as well as large chromosomal deletions, led to resistance...
against ceftazidime, albeit to a lower level than β-lactamase-dependent resistance (56). This aspect will have to be considered for the development of adjuvants leading to the decreased expression of ampC.

Nevertheless, the genes identified in our study provide promising candidates as targets for the development of novel adjuvants to restore the function of β-lactam antibiotics in MDR P. aeruginosa strains with high levels of AmpC activity.

MATERIALS AND METHODS

Bacterial strains and culture conditions. The bacterial strains and plasmids used in this study are listed in Table S2 in the supplemental material. Bacteria were cultivated overnight at 37°C with shaking at 200 rpm in lysogeny broth (LB) containing suitable antibiotics, if necessary. Overnight cultures were diluted 1:20 into LB containing suitable antibiotics or additives, like L-rhamnose, and grown for 3 h at 37°C and 200 rpm. The growth of bacteria in LB at 37°C in a 24-well plate was measured using a Tecan Infinite 200 Pro plate reader.

Whole-genome sequencing of the ID40 isolate. DNA isolation, library preparation, and Illumina sequencing of the ID40 strain have been described by Willmann et al. (22).

For Nanopore sequencing, the DNA was isolated using a DNeasy UltraClean microbial kit (Qiagen). Library preparation was conducted using a ligation sequencing kit (Oxford Nanopore Technologies). Sequencing was performed on a PromethION sequencer (Oxford Nanopore Technologies) on a FLO-PRO002 flow cell (version R9).

The ID40 genome was assembled using a hybrid assembly approach that combines the Nanopore long reads with exact Illumina short reads. We used the hybrid assembly pipeline pathoLogic (57) with default settings and selected Unicycler (58) as the main assembly algorithm. Further manual scaffolding yielded a single circular plasmid and a circular chromosome. The assembled genome as well as the plasmid sequence was annotated using the Prokka (version 1.11) software tool (59, 60).

Generation of ID40 Tn library. The ID40 Tn mutant library was generated as described previously (55, 61) with some modifications. The donor strain E. coli SM10 λ pir containing pBT20 was grown in LB containing 15 μg/ml gentamicin (Gm), and recipient strain ID40 was grown in LB. Cell suspensions of both strains were adjusted to an optical density at 600 nm (OD_{600}) of 2.0 and mixed, and droplets of 100 μl were spotted onto prewarmed LB agar plates. After incubation at 37°C for 3 h, the mating mixtures were scraped off the plate and resuspended in 12 ml LB. Aliquots of 100 μl were plated onto 100 LB agar plates containing 25 μg/ml irgasan and 75 μg/ml Gm. After overnight growth at 37°C, all colonies (approximately 5,000 per plate) were scraped off the LB agar, resuspended, and washed once in LB. To eliminate satellite colonies, 1 liter of LB containing 75 μg/ml Gm was inoculated with the suspension to an OD_{600} of 0.1 and grown to an OD_{600} of 1.2. The bacteria were washed once and adjusted to an OD_{600} of 22 in LB containing 20% glycerol, and finally, aliquots of 1 ml were frozen at −80°C.

Tn library antibiotic exposure. One aliquot of the Tn library was centrifuged, resuspended in LB, and grown in 100 ml LB overnight. The overnight cultures were diluted 1:100 into 100 ml LB with or without 8 μg/ml FEP or 2 μg/ml MEM and grown at 37°C. After 24 h, the cultures were diluted 1:100 into fresh LB and grown for another 24 h at 37°C to enrich the viable bacteria.

Library preparation for TraDIS. Genomic DNA of 5 × 10⁶ bacteria per sample was isolated using a DNeasy UltraClean microbial kit (Qiagen). Two micrograms of DNA per sample was sheared into fragments of 300 bp with an M220 Ultrasonicator (Covaris), and a cleanup was conducted with a 1.5-fold volume of Agencourt AMPure XP DNA beads (Beckman Coulter). End repair, A tailing, and adapter ligation were done using an NEBNext Ultra II DNA library preparation kit for Illumina (NEB). A splinkerette and the P7 indexed primer were used as adapters, leading to the enrichment of Tn-containing fragments in the PCR (62–64). Fragments were size selected using Agencourt AMPure beads and amplified by PCR with one Tn-specific primer and one index primer (Illumina) in 20 cycles using Kapa HiFi HotStart ReadyMix (Kapa Biosystems). The proper size distribution and quality of the samples were assessed with an Agilent DNA high-sensitivity kit on a 2100 bioanalyzer (Agilent Technologies). After a final cleanup, the concentration of total fragments and Tn-containing fragments was measured by quantitative PCR (qPCR) using a Kapa SYBR Fast qPCR master mix (2×) kit (Kapa Biosystems) with one P5-specific primer and one P7-specific primer or one Tn-specific primer and one P7-specific primer, respectively.

Sequencing. Samples were adjusted to 4 nM in resuspension buffer (Illumina), pooled, and denatured with 0.2 N NaOH. Subsequently, the library was diluted to 8 pM in hybridization buffer (Illumina) and sequenced with an MiSeq reagent kit (version 2; 50 cycles) on an MiSeq sequencer (Illumina) with a bacteriophage phiX (Illumina) spike in of 5% and dark cycles (62).

TraDIS data analysis. Sequencing reads containing the Tn tag were mapped against the ID40 reference genome, using the Bio:TraDIS pipeline (62), in order to determine the locations and numbers of Tn insertions. For each gene, an insertion index was calculated by dividing the number of insertions in a gene by the total gene length. The bimodal distribution of insertion indices allows the determination between essential and nonessential genes, as recently described (15, 65). Genes that fulfilled the cutoff criterion of an insertion index of <0.0019 for essential genes or an insertion index of >0.0026 for nonessential genes were categorized in these groups. All other genes were considered ambiguous (Data Set S2).

Statistical analysis was performed using DESeq2 software (https://bioconductor.org) (66). Differential gene expression analysis was performed for group comparisons of MEM versus the control and FEP
versus the control. Genes were categorized as differentially enriched or depleted if the adjusted P value was <0.05.

**Generation of in-frame deletion mutants.** In-frame deletion mutants were generated using the suicide plasmid pEXG2 (67) as described by Klein et al. (68). The primers used in this study are listed in Table S3.

**Generation of complementation constructs.** For complementation of the ctpA, mepM1, mtrG, and ygfB mutant strains, the coding sequences were amplified by PCR from genomic DNA of ID40 and were assembled with the plasmid pJM220 (pUC18T-minTn7T-gm-rhaSR-PrhaBAD) (69) by Gibson cloning. The constructed plasmids were transformed into E. coli SM10 λ pir and mobilized by conjugation into the mutant strains as described previously (70), with some modifications. A triparental mating was conducted by combining the recipient strain together with the mini-Tn7 harboring SM10 λ pir strain and SM10 λ pir/Tn53 harboring a Tn7 transposase. Insertion of the mini-Tn7 construct into the arfTn7 site was monitored by PCR. Excision of the pJM220 backbone containing the Gm resistance cassette was performed by expressing Flp recombinase from a conjugative plasmid, pFLP2. Finally, sucrose-resistant but Gm- and carbenicillin-sensitive colonies were verified by PCR.

**RNA isolation and qRT-PCR.** RNA isolation and quantitative reverse transcription-PCR (qRT-PCR) were performed as previously described (68).

**β-Lactamase activity assay.** A β-lactamase colorimetric activity assay (BioVision) based on nitrocefin turnover was performed according to the manufacturers’ instructions after dissolving the bacteria in 5-μl/mg β-lactamase assay buffer and diluting the supernatant of the sonified bacteria 1:50 in β-lactamase assay buffer.

**Antibiotic susceptibility testing.** For antibiotic susceptibility testing by broth microdilution, bacterial strains were grown overnight at 37°C in LB medium with or without 0.1% rhamnose. Physiological NaCl solution was inoculated to a McFarland standard of 0.5, and subsequently, 62.5 μl of the suspension was transferred into 15 ml Mueller-Hinton broth (with 0.1% rhamnose for the complemented strains) and mixed well. According to the manufacturer’s instructions, 50 to 100 μl of the suspension was transferred into each well of a broth microdilution microtiter plate (a Micronaut-S MHK Pseudomonas-2 [catalog number E1-099-100] or a Micronaut-S MHK Pseudomonas-2 [catalog number E1-111-040] plate [Merlin Diagnostic] or a Sensititre GN2F or Sensititre EUX2NF plate [Thermo Fisher Scientific]). The microtiter plates were incubated for 18 h at 37°C, and the OD600 was measured using a Tecan Infinite 200 Pro plate reader. Antibiotic strains were considered sensitive to the respective antibiotic concentration if an OD600 value below 0.05 was measured.

**Etests (Liofilchem) were conducted as previously described (68).**

**Statistics.** Statistics were performed using GraphPad Prism (version 7.04) software, as described for each experiment in the table or figure legends.

**Data availability.** The whole genome and the plasmid sequences were annotated and submitted to the European Nucleotide Archive (ENA) (accession number PRJEB32702). Similarly, all TraDIS sequence data were uploaded to ENA (accession number PRJEB32702). A more detailed description of the files is provided in Table S4.

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**SUPPLEMENTAL FILE 1**, PDF file, 0.9 MB.

**SUPPLEMENTAL FILE 2**, XLSX file, 0.1 MB.

**SUPPLEMENTAL FILE 3**, XLSX file, 0.01 MB.

**SUPPLEMENTAL FILE 4**, XLSX file, 0.03 MB.

**ACKNOWLEDGMENTS**

We thank Baris Bader and Christina Engesser for excellent technical support, Simon Heumos and Sven Nahnsen from the Quantitative Biology Center, University of Tübingen, for TraDIS data analyses, Lars Barquist for helpful discussion, Laura Nolan for providing plasmid pBT20, and Marina Borisova for providing the PAO1 strains.

This work was supported by the German Research Council (DFG) under grant SFB 766 to I.B.A. and M.S. and the German Center of Infection Research (DZIF) under grant 06.801 to M.S.

**REFERENCES**

1. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluymans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavalieri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, WHO Pathogens Priority List Working Group. 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18:318–327. https://doi.org/10.1016/S1473-3099(17)30753-3.

2. Yoshimura F, Nikaido H. 1982. Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes. J Bacteriol 152:636–642.

3. Strateva T, Yordanov D. 2009. Pseudomonas aeruginosa—a phenomenon of bacterial resistance. J Med Microbiol 58:1133–1148. https://doi.org/10.1099/jmm.0.009142-0.

4. Schmidtke AJ, Hanson ND. 2008. Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 52:3922–3927. https://doi.org/10.1128/AAC.00341-08.
Resistome of an MDR Pseudomonas aeruginosa Isolate

Antimicrobial Agents and Chemotherapy

March 2020 Volume 64 Issue 3 e01771-19

aac.asm.org 13

5. Tam VH, Schilling AN, LaRocco MT, Gentry LO, Lolas K, Quinn JP, Garey KW. 2007. Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 13:413–418. https://doi.org/10.1111/j.1469-0691.2006.01674.x.

6. Moya B, Dötches A, Juan C, Blazquez J, Zamorano L, Häussler S, Oliver A. 2009. Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog 5:e1000353. https://doi.org/10.1371/journal.ppat.1000353.

7. Hanson ND, Sanders CC. 1999. Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae. Curr Pharm Des 5:881–894.

8. Sanders CC, Sanders WE, Jr. 1986. Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics. J Infect Dis 154:792–800. https://doi.org/10.1093/infdis/154.5.792.

9. Livermore DM. 2002. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Investig Drugs 3:218–224.

10. Drawz SM, Bonomo RA. 2010. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23:160–201. https://doi.org/10.1128/CMR.00037-09.

11. Domonlaon R, Birkner S, Eisen B, Findl M, Garrel G, Schweiz J, Schmitz-Dilip K. 2019. Dilipid ultrashort cationic lipopeptides as adjuvants for chloramphenicol and other conventional antibiotics against Gram-negative bacteria. Amino Acids 51:383–393. https://doi.org/10.1007/s00726-018-2673-9.

12. Lydon HL, Baccile N, Callaghan B, Marchant R, Mitchell CA, Banat IM. 2017. The secondary resistome of multidrug-resistant Pseudomonas aeruginosa isolated from patients with bacteremia in a Spanish multicenter study. Antimicrob Agents Chemother 61:e02547-16. https://doi.org/10.1128/AAC.02547-16.

13. Lydon HL, Callaghan B, Marchant R, Mitchell CA, Banat IM. 2017. Adjuvant antibiotic activity of acidic sophorolipids with potential for facilitating wound healing. Antimicrob Agents Chemother 61:e00146-18. https://doi.org/10.1128/AAC.00146-18.

14. Maiden MM, Hunt AMA, Zachos MP, Gibson JA, Hurwitz ME, Mulks MH, Waters CM, Maiden MM, Hunt AMA, Zachos MP, Gibson JA, Hurwitz ME, Mulks MH, Waters CM. 2018. Triclosan is an aminoglycoside adjuvant for retarding uropathogenic Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 62:e00146-19. https://doi.org/10.1128/AAC.00146-19.

15. Baker RK, Jana B, Hansen AM, Vissing KN, Nielsen HM, Frantzik I, Guardabassi L. 2016. Repurposing antibacterial and rfpaminic against Gram-negative pathogens by combination with peptide potentiators. Int J Antimicrob Agents 61:216–224. https://doi.org/10.1016/j.ijantimicag.2018.10.025.

16. Vötsch W, Templin MF. 2000. Characterization of a beta-N-acetylglucosaminidase of Escherichia coli and its role in beta-lactamase expression. Antimicrob Agents Chemother 54:4915–4920. https://doi.org/10.1128/AAC.00097-00.

17. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O. 2009. Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals. J Microbiol 54:44–49. https://doi.org/10.1128/JMI.01227-05.5562-S.

18. Hassan KA, Cain AK, Huang T, Liu Q, Elbourne LDH, Boinett CJ, Brzoska A, Phan MD, Peters KM, Sarkar S, Lippman S, Singh PK, Flesch I, Markert U, Schmidt A, Kübler P, Haug M, Javed M, Jentzsch B, Beatson SA, Schembri MA. 2017. Recombinant S. enterica jac/dkx158 gene of Pseudomonas aeruginosa is associated with OprD polymorphisms, particularly the amino acid substitution at codon 70. J Antimicrob Chemother 72:2489–2495. https://doi.org/10.1093/jac/dkx158.

19. Lee SA, Gallagher LA, Staudinger BJ, Lippman S, Singh PK, Manoil C. 2015. General and condition-specific essential functions of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 112:5189–5194. https://doi.org/10.1073/pnas.1421916112.

20. Fernández-Piñar R, Lo Sciuto A, Rossi A, Ranucci S, Braugoni A, Imperi F. 2015. In vitro and in vivo screening for novel essential cell-envelope proteins in Pseudomonas aeruginosa. Sci Rep 5:17593. https://doi.org/10.1038/srep17593.

21. Odell J, Watkins PM. 2000. Characterization of a beta-N-acetylglucosaminidase of Escherichia coli and its role in beta-lactam resistance. Proc Natl Acad Sci U S A 97:12275–12280. https://doi.org/10.1073/pnas.151002597.

22. Kim CH, Kang HY, Kim BR, Jeon H, Lee YC, Lee SH, Lee JC. 2016. Blocking peptidoglycan recycling in Pseudomonas aeruginosa by combination with peptide potentiators. Int J Antimicrob Agents 62:101–106. https://doi.org/10.1016/j.ijantimicag.2018.10.025.

23. Lee SA, Felsch I, Markert U, Schmidt A, Kübler P, Haug M, Javed M, Jentzsch B, Beatson SA, Schembri MA. 2018. Blocking peptidoglycan recycling shortcut that bypasses peptidoglycan de novo biosynthesis. J Biol Chem 293:39302–39308. https://doi.org/10.1074/jbc.M118.004792000.

24. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Allan JP, Oliver A, Sin A, Javed M, Jentzsch B, Beatson SA, Schembri MA. 2011. AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 55:1990–1996. https://doi.org/10.1128/AAC.01688-10.

25. Kim CH, Kang HY, Kim BR, Jeon H, Lee YC, Lee SH, Lee JC. 2016. Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals. J Microbiol 54:44–49. https://doi.org/10.1128/JMI.01227-05.5562-S.

26. Hassan KA, Cain AK, Huang T, Liu Q, Elbourne LDH, Boinett CJ, Brzoska A, Phan MD, Peters KM, Sarkar S, Lippman S, Singh PK, Flesch I, Markert U, Schmidt A, Kübler P, Haug M, Javed M, Jentzsch B, Beatson SA, Schembri MA. 2017. Recombinant S. enterica jac/dkx158 gene of Pseudomonas aeruginosa is associated with OprD polymorphisms, particularly the amino acid substitution at codon 70. J Antimicrob Chemother 72:2489–2495. https://doi.org/10.1093/jac/dkx158.

27. Jones AD, Cawkwell RA, Brough SJ, Jardine AD, Dibben C. 2016. Genomewide identification of genetic determinants of antimicrobial resistance and elucidation of its role in muropeptide recycling and beta-lactamase induction. J Biol Chem 281:1355–1361. https://doi.org/10.1074/jbc.M115.682171.

28. Goris J, Schneider A, Nagele B, Dorischa M, Mayer C. 2013. A cell wall recycling shortcut that bypasses peptidoglycan de novo biosynthesis. Nat Chem Biol 9:491–493. https://doi.org/10.1038/nchembio.1289.

29. Lee SA, Felsch I, Markert U, Schmidt A, Kübler P, Haug M, Javed M, Jentzsch B, Beatson SA, Schembri MA. 2018. Blocking peptidoglycan recycling in Pseudomonas aeruginosa by combination with peptide potentiators. Int J Antimicrob Agents 62:101–106. https://doi.org/10.1016/j.ijantimicag.2018.10.025.
doglycan recycling pathway leading to intrinsic fosfomycin resistance. mBio 8:e00092-17. https://doi.org/10.1128/mBio.00092-17.

41. Fumeaux C, Bernhardt TG. 2017. Identification of MupP as a new peptidoglycan recycling factor and antibiotic resistance determinant in Pseudomonas aeruginosa. mBio 8:e00102-17. https://doi.org/10.1128/mBio.00102-17.

42. Cavallari JF, Lamers RP, Scheuwer EM, Matos AL, Burrows LL. 2013. Changes to its peptidoglycan-remodeling enzyme repertoire modulate beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 57:3078–3084. https://doi.org/10.1128/AAC.00268-13.

43. Srivastava D, Seo J, Rimal B, Kim SJ, Zhen S, Darwin AJ. 2018. A proteolytic complex targets multiple cell wall hydrolases in Pseudomonas aeruginosa. mBio 9:e00972-18. https://doi.org/10.1128/mBio.00972-18.

44. Zincke D, Balasubramanian D, Silver LL, Mathee K. 2016. Characterization of a carboxenem-hydrolyzing enzyme, PoxB, in Pseudomonas aeruginosa PA01. Antimicrob Agents Chemother 60:936–945. https://doi.org/10.1128/AAC.01807-15.

45. Mayer C. 2019. Peptidoglycan recycling, a promising target for antibiotic adjuants in antimicrobial therapy. J Infect Dis 220:1717–1715. https://doi.org/10.1093/infdis/jiz278.

46. Lamers RP, Nguyen UT, Nguyen Y, Buenosuco RN, Burrows LL. 2015. Loss of membrane-bound lytic transglycosylases increases outer membrane permeability and beta-lactam sensitivity in Pseudomonas aeruginosa. Microbiolobiogeny 4:879–895. https://doi.org/10.1002/mib.286.

47. Dhar S, Kumari H, Balasubramanian D, Mathee K, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prijibelski AD, Pyskhn AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPA:es: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477. https://doi.org/10.1089/cmb.2012.0021.

48. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30:2668–2669. https://doi.org/10.1093/bioinformatics/btu153.

49. Devoss NJ, Bryant AL, Kolasinski KM, O’Meara A, Amanat S, Ausubel FM. 2012. Genome-wide identification of anti-sigma factor mutations in Pseudomonas aeruginosa and Vibrio cholerae. J Bacteriol 194:6606–6615. https://doi.org/10.1128/JB.00597-12.

50. Perley-Robertson GE, Yadav AK, Winogrodzki JL, Stubbs KA, Mark BL, Thuombar K, Walther S, Furey MW, Giusti CA, Freese SD, DePamphilis CL. 2009. Splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat Protoc 4:789–798. https://doi.org/10.1038/nprot.2009.64.

51. Devon RS, Porteous DJ, Brooks AJ. 1995. Splinkerettes—improved vectors for greater efficiency in PCR walking. Nucleic Acids Res 23:6266–6270. https://doi.org/10.1093/nar/23.24.6266.

52. Sonnabend MS, Frank L, Leibiger K, Franz-Wachtel M, Macek B, Klein K, Guldner D, Zehnder AL, Madsen CL, Reiken SL, Lewis L, Bartram A, Formal J, Vogel W, Dörfel D, Berger L, Ma RN, Wittmann M, Hengartner C, Gut I, Gut M, Autenrieth I, Ossowskis S. 2019. Tracking of antibiotic resistance transfer and rapid plasmid evolution in a hospital setting by Nanopore sequencing. bioRxiv https://doi.org/10.1101/639609.

53. Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Uncycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol 13:e1005595. https://doi.org/10.1371/journal.pcbi.1005595.

54. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prijibelski AD, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477. https://doi.org/10.1089/cmb.2012.0021.

55. Frauenfelder T. 2017. Identification of MltG as a potential additional RND resistance efflux pump in Pseudomonas aeruginosa and other RND resistance efflux pumps. mBio 8:e00102-17. https://doi.org/10.1128/mBio.00102-17.

56. Kabot G, Florit-Mendoza L, Sanchez-Diener I, Zamorano L, Oliver A. 2018. Deciphering beta-lactamase-independent beta-lactam resistance evolution trajectories in Pseudomonas aeruginosa. J Antimicrob Chemother 73:3322–3331. https://doi.org/10.1093/jac/dky364.

57. Peter S, Bosio M, Gross C, Bezdan D, Gutierrez J, Oberhettinger P, Lise J, Voytel W, Dörfel D, Berger L, Ma RN, Wittmann M, Gut I, Gut M, Autenrieth I, Ossowskis S. 2019. Tracking of antibiotic resistance transfer and rapid plasmid evolution in a hospital setting by Nanopore sequencing. bioRxiv https://doi.org/10.1101/639609.